drugset
drugset / Trial / NCT02207595

Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects

NCT02207595 ↗

Phase 1 Completed 60 enrolled UCB Celltech Parexel · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

The primary objective of this study is to investigate the safety and tolerability of UCB5857.

Timeline

Start
2014-08
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject seletalisib Small molecule 5 mg Oral
Subject seletalisib Small molecule 10 mg Oral
Subject seletalisib Small molecule 20 mg Oral
Subject seletalisib Small molecule 30 mg Oral
Subject seletalisib Small molecule 50 mg Oral
Subject seletalisib Small molecule 100 mg Oral

Indications

No indication recorded.